BR0317623A - Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram - Google Patents

Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram

Info

Publication number
BR0317623A
BR0317623A BR0317623-1A BR0317623A BR0317623A BR 0317623 A BR0317623 A BR 0317623A BR 0317623 A BR0317623 A BR 0317623A BR 0317623 A BR0317623 A BR 0317623A
Authority
BR
Brazil
Prior art keywords
escitalopram
pharmaceutical composition
hydrobromide
hydrobrometh
citalopram
Prior art date
Application number
BR0317623-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Lawrence Martel
Robert Dancer
Hans Petersen
Peter Ellegaard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32668635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0317623(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BR0317623A publication Critical patent/BR0317623A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR0317623-1A 2002-12-23 2003-12-18 Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram BR0317623A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200202005 2002-12-23
PCT/DK2003/000902 WO2004056791A1 (en) 2002-12-23 2003-12-18 Escitalopram hydrobromide and a method for the preparation thereof

Publications (1)

Publication Number Publication Date
BR0317623A true BR0317623A (pt) 2005-11-29

Family

ID=32668635

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317623-1A BR0317623A (pt) 2002-12-23 2003-12-18 Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram

Country Status (32)

Country Link
US (1) US20040167209A1 (https=)
EP (1) EP1578738B1 (https=)
JP (2) JP4658613B2 (https=)
KR (1) KR20050086933A (https=)
CN (1) CN100349885C (https=)
AR (1) AR042652A1 (https=)
AT (1) ATE388947T1 (https=)
AU (1) AU2003287919B2 (https=)
BR (1) BR0317623A (https=)
CA (1) CA2511142A1 (https=)
CY (1) CY1107451T1 (https=)
DE (1) DE60319739T2 (https=)
DK (1) DK1578738T3 (https=)
EA (1) EA013116B1 (https=)
EG (1) EG24729A (https=)
ES (1) ES2298595T3 (https=)
IL (1) IL169125A0 (https=)
IS (1) IS2654B (https=)
ME (1) MEP5808A (https=)
MX (1) MXPA05005772A (https=)
MY (1) MY135468A (https=)
NO (1) NO20053595L (https=)
NZ (1) NZ540281A (https=)
PE (1) PE20040924A1 (https=)
PL (1) PL378275A1 (https=)
PT (1) PT1578738E (https=)
RS (1) RS51092B (https=)
TW (1) TW200501943A (https=)
UA (1) UA80170C2 (https=)
UY (1) UY28148A1 (https=)
WO (1) WO2004056791A1 (https=)
ZA (1) ZA200504109B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80170C2 (en) * 2002-12-23 2007-08-27 Lundbeck & Co As H Escitalopram hydrobromide
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
AU2005218713B2 (en) * 2004-03-05 2009-11-19 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
AU2006304889A1 (en) * 2005-10-14 2007-04-26 H. Lundbeck A/S Stable pharmaceutical formulations containing escitalopram and bupropion
EP1954257A4 (en) * 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
ES2687756T3 (es) * 2006-07-11 2018-10-29 Mitsubishi Tanabe Pharma Corporation Sal de un compuesto de morfolina
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
FR3006594A1 (fr) * 2013-06-11 2014-12-12 Sorin Crm Sas Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
RU2020111694A (ru) * 2017-10-09 2021-11-12 Тева Фармасьютикал Индастриз Лтд. Новые соли и твердые формы эсциталопрама
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34712A (en) * 1862-03-18 James h
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
CA2291134C (en) * 1998-10-20 2006-05-23 H. Lundbeck A/S Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
TR200401456T1 (tr) * 1999-10-25 2005-04-21 H. Lundbeck A/S Sitalopram hazırlanması için yöntem.
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
JP2002020379A (ja) * 2000-05-02 2002-01-23 Sumika Fine Chemicals Co Ltd シタロプラム臭化水素酸塩の結晶およびその結晶化方法
IES20010693A2 (en) * 2000-08-10 2002-07-10 Lundbeck & Co As H Pharmaceutical composition containing citalopram
BR0115907B1 (pt) * 2000-12-04 2011-10-04 processo para o tratamento prévio de óleos crus e graxas cruas para uma subsequente transesterificação alcalina com álcoois primários e/ou secundários e processo para a produção de ésteres de ácido graxo de álcoois primários e/ou secundários a partir de óleos crus ou graxas cruas que contém ácidos graxos livres e substáncias mucilaginosas ou a partir de óleos velhos carregados com ácidos graxos livres da indústria alimentìcia.
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
UA80170C2 (en) * 2002-12-23 2007-08-27 Lundbeck & Co As H Escitalopram hydrobromide
US20050174782A1 (en) * 2003-03-25 2005-08-11 Chapman Leonard T. Flashlight

Also Published As

Publication number Publication date
CA2511142A1 (en) 2004-07-08
EA200501046A1 (ru) 2005-12-29
US20040167209A1 (en) 2004-08-26
DE60319739T2 (de) 2008-07-17
TW200501943A (en) 2005-01-16
JP2011037893A (ja) 2011-02-24
CN100349885C (zh) 2007-11-21
MEP5808A (xx) 2010-02-10
NZ540281A (en) 2008-07-31
JP2006514952A (ja) 2006-05-18
CY1107451T1 (el) 2012-12-19
DE60319739D1 (de) 2008-04-24
PL378275A1 (pl) 2006-03-20
DK1578738T3 (da) 2008-06-30
IL169125A0 (en) 2009-02-11
MY135468A (en) 2008-04-30
PT1578738E (pt) 2008-04-11
RS20050487A (sr) 2007-06-04
EA013116B1 (ru) 2010-02-26
EP1578738A1 (en) 2005-09-28
HK1087708A1 (en) 2006-10-20
PE20040924A1 (es) 2004-12-11
RS51092B (sr) 2010-10-31
IS2654B (is) 2010-08-15
AU2003287919B2 (en) 2009-11-12
EG24729A (en) 2010-06-21
KR20050086933A (ko) 2005-08-30
ZA200504109B (en) 2006-08-30
CN1726202A (zh) 2006-01-25
WO2004056791A1 (en) 2004-07-08
EP1578738B1 (en) 2008-03-12
JP4658613B2 (ja) 2011-03-23
AR042652A1 (es) 2005-06-29
MXPA05005772A (es) 2005-08-16
ATE388947T1 (de) 2008-03-15
NO20053595L (no) 2005-09-05
UY28148A1 (es) 2004-09-30
ES2298595T3 (es) 2008-05-16
UA80170C2 (en) 2007-08-27
IS7848A (is) 2005-05-17
AU2003287919A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
PA8539901A1 (es) Novedosa sal de succinato de o-desmetil-venlafaxina
BR0317623A (pt) Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram
BR0116831A (pt) Composição oral e seu uso
AR021981A1 (es) Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
NO20025450L (no) Ny farmasöytisk sammensetning
MEP39108A (en) Pharmaceutical composition
MA26937A1 (fr) Nouvelle composition pharmaceutique.
ECSP045491A (es) Nueva sal formiato de o-desmetil venlafaxina
BR0109041B1 (pt) composições de policarbonato, uso das mesmas e uso de materiais inorgánicos.
PT1112266E (pt) 4-amino-2-aril-pirimidinas substituidas, sua preparacao, sua utilizacao e composicoes farmaceuticas que as contem.
SV2002000776A (es) Nuevas imidazotriazinonas sustituidas ref.lea 34 985-sv
HRP20030154B1 (en) Preparation of risperidone
BR9909486A (pt) Compostos calcilìticos
BR0314058A (pt) Composições para cuidados pessoais a base de álcool ramificado
DOP2002000457A (es) Tetrahidroquinolinas
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva
BR0114814A (pt) Composições compreendendo composto de modafinila e seu uso
BR0213278B1 (pt) composição vedante e seu uso.
ES2187489T3 (es) Composiciones farmaceuticas a base de diclofenac.
ITRM950273A0 (it) Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni farmaceutiche.
ES2060293T3 (es) Nueva sustancia antiulcerosa.
BR0011261B1 (pt) composiÇço oral compreendendo perlita, e, uso de perlita.
CL2004001317A1 (es) Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h
BR0115281A (pt) Composições de n-(metiletilaminocarbonil)-4-(3-metilfenilamino)-3piri dilsulfonamida e oligossacarìdeos cìclicos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.